"The Perseus Group is a small multidisciplinary team of experts from various fields including medicine, pharmaceutical manufacture and regulation, and safety management. The Group, formed in September 2022, comprises individuals with shared concerns about the safety of the Covid-19 vaccine and medicines in general and MHRA’s remit to keep patients safe."
Topics addressed in this statement include vaccine safety, vaccine pharmacovigilance, over-promotion (of vaccines), and lack of transparency.
"This statement covers our concerns about Covid-19 vaccine safety, MHRA’s authorisation of the Covid-19 vaccines, its post-Authorisation surveillance and lessons we believe can be learned from best practice safety management in other safety critical sectors...
Summary
158. The much shorter than normal clinical trials left significant residual safety risks because key tests were omitted.
159. There was inadequate critical assessment of the manufacturers’ trials data...
162. Insufficient regard was paid to younger age groups’ very low risk from Covid-19. In particular, we believe that the vaccination of children was never justifiable given the absence of medium/long term safety data and flimsy evidence about the effect of vaccination on transmission...
164. MHRA seems oblivious to potential safety signals from population-level data, including official UK data and ‘control groups’ such as Australia and Singapore.
165. The significant and sustained excess deaths since July 2021 (more than in the whole of 2020) remain unexplained.
166. Safety and effectiveness of the Covid-19 vaccines and effect on transmission were overestimated and over-promoted...
168. Deaths and serious harms from the Covid-19 vaccines have been far from rare.
169. There has been a lack of transparency regarding key safety documents."